menu
    • menu
    [{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Emalex Bioscience

    Menu

    Emalex Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

                            Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for certain central nervous system disorders, by blocking the action of the neurotransmitter dopamine at the D1 receptor.

                            Product Name : EBS-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 01, 2023

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

                            Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for Tourette Syndrome, by blocking the action of the neurotransmitter dopamine at the D1 receptor.

                            Product Name : EBS-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 10, 2023

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome

                            Details : Ecopipam hydrochloride is a first-in-class dopamine-1 receptor antagonist which blocks the actions of the neurotransmitter dopamine at the D1 receptor. It is currently approved to treat tourette syndrome.

                            Product Name : EBS-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : University of California

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disord...

                            Details : The study is evaluating ecopipam, an investigational first-in-class drug, to determine whether it may help improve the ability to get words out without stuttering.

                            Product Name : EBS-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 14, 2021

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : University of California

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Emalex Bioscience

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : University of California

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

                            Details : First adult patient has been dosed in its Phase 2 clinical trial evaluating ecopipam, the company’s investigational medicine, for the treatment of childhood-onset fluency disorder, or “stuttering.”

                            Product Name : EBS-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 15, 2020

                            Lead Product(s) : Ecopipam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : University of California

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth